{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/boils-carbuncles-staphylococcal-carriage/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"50f6d537-c403-5492-8f76-60f0d289311b","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field 0dab75f4-9609-4bd1-be5b-5c603ac3a81d --><h2>Erythromycin</h2><!-- end field 0dab75f4-9609-4bd1-be5b-5c603ac3a81d -->","summary":"","htmlStringContent":"<!-- begin item 8801f140-df57-465b-ada5-61df6abebfa9 --><!-- end item 8801f140-df57-465b-ada5-61df6abebfa9 -->","topic":{"id":"54075b27-a21e-51d3-9baa-7fbf14bd66dc","topicId":"0d3dc61f-e642-42db-86ab-135b0904e326","topicName":"Boils, carbuncles, and staphylococcal carriage","slug":"boils-carbuncles-staphylococcal-carriage","lastRevised":"Last revised in January 2021","chapters":[{"id":"f0074c02-54ce-5eb0-b6bf-9be2416ad2dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ddce60fa-ff81-52a9-8e0d-f55e16535b62","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"385a9012-a1f9-5136-9616-03c449913f6a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"45262b9a-71d4-53b5-a9f6-b41e4f708f00","slug":"changes","fullItemName":"Changes"},{"id":"7aea9ee9-443a-5a1b-a316-1c124a0f6f17","slug":"update","fullItemName":"Update"}]},{"id":"a535700a-66cc-5262-a015-fa82a0fcc759","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9feb709-03bc-50df-b1d9-f53eb04978d7","slug":"goals","fullItemName":"Goals"},{"id":"d5bf23a9-18a2-5447-8684-7554c58876c4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a09fbba4-c9a1-5e3f-b1cd-0a60b9b4d0a7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e50a6290-cf66-5b66-9c8d-ddb45c39739e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bb83d31d-b3f2-58e1-8914-de7c5da42e71","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c2fba1e8-8a17-5a24-b4f0-2fddc978300d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b9d58fbb-15fe-5908-b37f-1f5accb0ec82","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a65c96cf-0291-5b1f-b80f-cabd4c78a221","slug":"definition","fullItemName":"Definition"},{"id":"114ea721-bbbe-5fab-a7c5-e3a3cdf9b8cd","slug":"causes","fullItemName":"Causes"},{"id":"4416bba3-46db-503e-8bff-671b6840dc98","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bf0d2335-8eb7-5bbc-9e3b-5b1360259d6b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3a3b9ed3-6200-5833-91c9-c7d7c5f0ed19","slug":"prognosis","fullItemName":"Prognosis"},{"id":"256b369a-1872-5879-9ee3-8540d2c9eba4","slug":"complications","fullItemName":"Complications"},{"id":"ee205ab9-1b45-53bb-b58d-2b5c66e16e0d","slug":"staphylococcal-carriage","fullItemName":"Staphylococcal carriage"}]},{"id":"fbdde5c0-e8b4-53b6-8d34-db66527d0e5f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c21ee7cd-4f65-5ae2-a691-8e31d9552fda","slug":"clinical-presentation-of-a-boil","fullItemName":"Clinical presentation of a boil"},{"id":"abb3f60f-a2e6-5ead-817c-41d325a79a68","slug":"clinical-presentation-of-a-carbuncle","fullItemName":"Clinical presentation of a carbuncle"},{"id":"29709694-4ae1-52e7-aff9-c930ebe00e48","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"89236346-a81c-5714-a669-d65dce0742fc","fullItemName":"Management","slug":"management","subChapters":[{"id":"795838e3-56e5-5218-8cc1-54916fca77b5","slug":"boils-carbuncles","fullItemName":"Scenario: Boils and carbuncles"},{"id":"9f739273-9519-5dce-b02d-d119fffd9e88","slug":"staphylococcal-carriage","fullItemName":"Scenario: Staphylococcal carriage"}]},{"id":"25985e4b-4b2e-52c7-9074-44d8d2956cf7","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"23fc6648-429c-5e60-89d2-c934ffccb7c1","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"c609a36f-26e7-5976-bce4-d9cc3212b1cf","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"50f6d537-c403-5492-8f76-60f0d289311b","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"43e0860e-28e8-5244-a63f-8d179dc64115","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dbf0c97f-a2a7-518b-88ae-d1d4390ba653","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7f2420de-0f7f-5d48-b0f7-c2bb46547a9d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6ffd38d3-be53-5fe6-97a9-415b9ae3f2d8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3e96917e-babd-54f3-bb44-e1c8e16c1c94","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6718ce9c-5275-5f33-940b-63a751aedd8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4ebad680-b095-5513-83d2-80f050748d07","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9189cfa4-d2b6-5288-98f8-5e6e6e1ebd0e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"25985e4b-4b2e-52c7-9074-44d8d2956cf7","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"92a84445-8fcb-53e8-be9e-c490e4c8863d","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field f5221fcb-7fbd-450d-907b-3ead1ea5c02a --><h3>Doses</h3><!-- end field f5221fcb-7fbd-450d-907b-3ead1ea5c02a -->","summary":"","htmlStringContent":"<!-- begin item 9c0aeb35-6a2d-439e-ab00-bfe06f198b93 --><!-- begin field b53447f3-95ad-4647-874d-e82c172bafa8 --><ul><li>Erythromycin doses:<ul><li>Adults and children older than 8 years of age — 250 mg to 500 mg, four times a day for 7 days.</li><li>Children 2–8 years of age — 250 mg, four times a day for 7 days (dose can be doubled in severe infection).</li><li>Children 1 month to 2 years of age — 125 mg, four times a day for 7 days (dose can be doubled in severe infection).</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">BNF for Children, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">BNF 72, 2016</a>]</p><!-- end field b53447f3-95ad-4647-874d-e82c172bafa8 --><!-- end item 9c0aeb35-6a2d-439e-ab00-bfe06f198b93 -->","subChapters":[]},{"id":"4af90a0d-3c4b-529f-9818-bbf138195d00","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e1ca07bb-9afc-4008-bad4-a6d500d471e4 --><h3>Contraindications and cautions</h3><!-- end field e1ca07bb-9afc-4008-bad4-a6d500d471e4 -->","summary":"","htmlStringContent":"<!-- begin item e3994b97-bc26-4990-8f18-a6d500d46f10 --><!-- begin field fbcd1121-01b5-4d86-a26e-a6d500d471e4 --><ul><li><strong>Do not prescribe erythromycin</strong> to people with:<ul><li>Porphyria or a known hypersensitivity to erythromycin.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval — macrolides can also prolong the QT interval, increasing the risk of Torsades de Pointes arrhythmia.</li></ul></li><li><strong>Prescribe erythromycin with caution</strong> in people with:<ul><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is principally excreted by the liver. </li><li>Renal impairment — give a maximum of 1.5 g daily in severe renal impairment due to the risk of ototoxicity. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate weakness symptoms of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">MHRA, 2020</a>]</p><!-- end field fbcd1121-01b5-4d86-a26e-a6d500d471e4 --><!-- end item e3994b97-bc26-4990-8f18-a6d500d46f10 -->","subChapters":[]},{"id":"0c8e6959-9059-575f-bb8e-4848378f7aaf","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d8fa91d8-252d-4189-be63-a6d500d55a0e --><h3>Adverse effects</h3><!-- end field d8fa91d8-252d-4189-be63-a6d500d55a0e -->","summary":"","htmlStringContent":"<!-- begin item 3c736e45-9d1d-474d-bb38-a6d500d55754 --><!-- begin field 2cb7a382-c2d8-4331-854c-a6d500d55a0e --><ul><li>Gastrointestinal adverse effects such as nausea, vomiting, and diarrhoea, are common in people taking erythromycin.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with erythromycin.</li><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with this drug.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">BNF 72, 2016</a>]</p><!-- end field 2cb7a382-c2d8-4331-854c-a6d500d55a0e --><!-- end item 3c736e45-9d1d-474d-bb38-a6d500d55754 -->","subChapters":[]},{"id":"6ad152a1-1692-56b0-91fb-8dc9f80d8838","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 42d47ab8-0b14-4fa4-bb14-a6d500d5772b --><h3>Drug interactions</h3><!-- end field 42d47ab8-0b14-4fa4-bb14-a6d500d5772b -->","summary":"","htmlStringContent":"<!-- begin item a0de9ffc-bde1-4880-b7e7-a6d500d5745c --><!-- begin field 8927028a-2301-49fb-b75f-a6d500d5772b --><ul><li><strong>Drug interactions with erythromycin include:</strong><ul><li><strong>Tolterodine, mizolastine, amisulpride, domperidone, ergotamine, dihydroergotamine, or pimozide </strong>— concurrent administration with erythromycin is contraindicated.</li><li><strong>Cimetidine </strong>— monitor concurrent use closely as a dose reduction of erythromycin may be necessary. Cimetidine may inhibit the metabolism of erythromycin, leading to an increased plasma concentration.</li><li><strong>Calcium channel blockers (CCBs) </strong>— due to an increased risk of hypotension, caution is advised with the concurrent use of erythromycin and CCBs metabolised by CYP3A4 (such as verapamil).</li><li><strong>Colchicine </strong>— avoid concurrent use if possible. Colchicine toxicity has been reported following concomitant use with erythromycin.</li><li><strong>Carbamazepine </strong>— avoid the concurrent use unless carbamazapine levels can be closely monitored and suitable dose reductions made. Erythromycin can increase carbamazepine levels by as much as 5-fold, causing carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness).</li><li><strong>Drugs that prolong the QT interval </strong>— if possible, avoid giving erythromycin to a person who is already taking a drug that can potentially prolong the QT interval.</li><li><strong>Statins </strong>— there is an increased risk of myopathy.<ul><li>For simvastatin — do not prescribe erythromycin to a person taking simvastatin. Consider temporarily stopping simvastatin during short-term treatment with erythromycin. </li><li>For atorvastatin — avoid concurrent use with erythromycin if possible. Consider temporarily stopping atorvastatin during short-term treatment with erythromycin. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>For pravastatin — prescribe erythromycin with caution and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Other statins — clinically significant interaction with erythromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness. </li></ul></li><li><strong>Theophylline </strong>— consider using clarithromycin (in preference to erythromycin) as clarithromycin normally causes only modest (clinically unimportant) increases in theophylline levels.<ul><li>Concurrent use of erythromycin with high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity (which may present as palpitations, nausea, tremor, and headache). If this is suspected, reduce the dose of theophylline. </li><li>Concurrent treatment may also result in a significant decrease in erythromycin serum concentrations, leading to sub-therapeutic concentrations of erythromycin.</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— monitor the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. Erythromycin may enhance the effect of warfarin; this is an established but unpredictable interaction.</li><li><strong>Zopiclone </strong>— monitor concurrent use. Erythromycin has been reported to decrease the clearance of zopiclone and this may lead to an increase in the effects of zopiclone. </li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are not required during or after courses of erythromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/boils-carbuncles-staphylococcal-carriage/references/\">MHRA, 2020</a>]</p><!-- end field 8927028a-2301-49fb-b75f-a6d500d5772b --><!-- end item a0de9ffc-bde1-4880-b7e7-a6d500d5745c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}